Remarks

Claims 1-6 and 8 have been amended, claims 7 and 9 have been canceled, and new claims 10-20 have been added.

No new matter has been added by these amendments.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

Respectfully submitted,

David Saliwanchik

David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606

DRS/la

Marked-up Version of amended claims

2. The [A] material according to claim 1, wherein the purifying comprises obtaining the 1-30 kD fraction.

3. The [A] material according to claim 1, wherein the purifying comprises obtaining the 10-20 kD fraction.

4. The [A] material according to claim 3, wherein the purifying additionally comprises ion exchange chromatography, and collecting the fraction eluted in 0.1-0.2 M NaCl.

5. The [A] material according to claim 1, wherein the purifying comprises the following protocol:

plasma cleared by centrifugation;

cleared plasma spun to give a nominal 0-30 kD fraction;

nominal 0-30 kD fraction spun to give a nominal 10-30 kD sub-fraction;

nominal 10-30 kD sub-fraction concentrated and gel-filtered to give a nominal 10-20 kD sub-fraction;

nominal 10-20 kD sub-fraction repeatedly concentrated and buffer-diluted, applied to an ion exchange column eluted with a gradient of 0-.3 M NaCl; and

eluate divided into 0-0.1 M, 0.1-0.2 M and 0.2-0.3 M NaCl ion exchange fractions.

6. The [A] material according to [any preceding claim] claim 1, wherein the mammal is a sheep.

8. A pharmaceutical composition comprising a material having the ability to reduce organ mass, the material being obtainable by:

collecting ovarian venous blood from a female mammal;

preparing ovarian venous plasma from the blood; and

at least partially purifying said material from the plasma

[according to any of claims 1 to 6] and a pharmaceutically acceptable excipient or carrier.